Please upgrade your browser.
The SWITCH trial makes it official: it makes no difference whether patients with metastatic renal cell carcinoma (mRCC) first start on sorafenib and then switch to sunitinib upon progression or vice versa.
Prognostic Tools that Help Make Sense of Localized RCC Heterogeneity, Guide the Decision-Making Process
One of the greatest challenges clinicians face in treating patients with small renal masses is to make sense of tumor heterogeneity and determine how best to treat these individuals.
Left ventricular infiltration from thyroid papillary carcinoma mimicking the electrocardiographic changes of acute myocardial infarction
No abstract (ahead of publication)
Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management
Purpose Approximately 5% to 8% of renal cell carcinoma (RCC) is hereditary. No guidelines exist for patient selection for RCC germline mutation testing. We evaluate how age of onset could indicate the need for germline mutation testing for detection of inherited forms of kidney cancer.
Obesity increases risk for clear-cell renal cell carcinoma, but obese patients appear to experience longer survival than nonobese patients. Why the paradox?
Dr Vincent Launay-Vacher - Pitie-Salpetriere Hospital, Paris, France
Dr Ari Hakimi - Memorial Sloan-Kettering Cancer Center, New York, USA
Primo Lara, MD, of the UC Davis Comprehensive Cancer Center, counts down the top five successes and disappointments in the past 20 years of renal cancer research. High on the list of successes: multispecialty coordination in renal cancer research and patient care.
"By working together and sharing information, we can transform medicine in ways that were unimaginable a decade ago."
In patients with organ transplantation as compared to the general population the risk of cancer is significantly increased.
|Powered by NeonCRM|